GLUE - Monte Rosa Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart

GLUE is currently covered by 7 analysts with an average price target of $28.67. This is a potential upside of $19.3 (205.98%) from yesterday's end of day stock price of $9.37.

Monte Rosa Therapeutics's activity chart (see below) currently has 37 price targets and 49 ratings on display. The stock rating distribution of GLUE is 95% BUY and 5% HOLD.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 58.55% of the time, taking 399.18 days on average.

Highest price target for GLUE is $37, Lowest price target is $22, average price target is $28.67.

Most recent stock forecast was given by DEREK ARCHILA from WELLS FARGO on 06-Nov-2026. First documented stock forecast 19-Jul-2021.

Best performing analysts who are covering GLUE - Monte Rosa Therapeutics:

Edward Tenthoff Eric Joseph Monte Rosa Kelly Shi Robert Driscoll

Currently out of the existing stock ratings of GLUE, 1 are a HOLD (5%), 19 are a BUY (95%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 08-Jan-2026

$25

$15.63 (166.81%)

$27

10 days ago
(06-Nov-2026)

5/9 (55.56%)

$14.43 (136.52%)

603

Buy Since 01-Oct-2026

$25

$15.63 (166.81%)

$25

1 months 11 days ago
(05-Oct-2026)

0/2 (0%)

$14.73 (143.43%)

Buy Since 15-Feb-2024

$27

$17.63 (188.15%)

$27

2 months 7 days ago
(09-Sep-2026)

3/6 (50%)

$12.74 (89.34%)

506

Buy Since 03-Jan-2022

$28

$18.63 (198.83%)

$28

2 months 22 days ago
(25-Aug-2026)

0/6 (0%)

$13.44 (92.31%)

Buy Since 11-May-2026

$27

$17.63 (188.15%)

$31

3 months 9 days ago
(07-Aug-2026)

0/2 (0%)

$11.12 (70.03%)

Show more analysts

Please expand the browser size to see the chart

What is GLUE (Monte Rosa Therapeutics) average time for price targets to be met?

On average it took 399 days for the stock forecasts to be reached, with an average price target met ratio of 58.55%.

Which analyst most recently updated their price target on GLUE (Monte Rosa Therapeutics)?

Derek Archila

Which analyst has the most public recommendations on GLUE (Monte Rosa Therapeutics)?

Derek Archila works at WELLS FARGO and has 2 price targets and 3 ratings on GLUE

Which analyst is the currently most bullish on GLUE (Monte Rosa Therapeutics)?

Edward Tenthoff with the highest potential upside of $27.63

Which analyst is the currently most reserved on GLUE (Monte Rosa Therapeutics)?

Monte Rosa with the lowest potential downside of -$2.29
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?